Use of compounds in a dry powder inhaler
CA 2457717 A1 · Owner: Pfizer Limited · Inventors: Humphrey, Michael John; Miller, Paul Robert; Shepherd, Michael Trevor
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo3,4-c-1,2,4- triazolo4,3-apyridines which is capable of delivering the compound as fine solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compounds in solution metered dose inhalers which response can prevent the administration of a therapeutically effective dose and, in the long term, undermine patient compliance.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 2, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 2, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 2, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.